■多发性硬化症(MS)的患病率正在全球增加。
■使用我们经过验证的基于处方的确定方法来确定澳大利亚的患病率是否持续增加。
■我们使用了2010年和2017年患病率估计中采用的方法。从澳大利亚2021年1月至12月的药物福利计划数据中提取了疾病修饰疗法(DMT)处方。使用来自澳大利亚MS纵向研究的数据计算DMT外显率。我们将每月处方总数除以12或2(阿仑珠单抗除外),根据DMT外显率和澳大利亚人口估计进行了调整。澳大利亚各州/领地的患病率是年龄标准化的。使用泊松回归将2021年患病率估计值与2010年和2017年患病率估计值进行比较。
■2021年,澳大利亚的MS人数为33,335;比2017年增加7728人(30.2%),比2010年增加12,092人(56.6%),并且增长速度快于人口变化(10.1%,+14.1%)。年龄标准化患病率为136.1/100,000(从2017年的103.7/100,000增加)。先前在2010年和2017年表现出的正纬度梯度在2021年持续存在,塔斯马尼亚(最南端的州)的患病率最高(年龄标准化:203.5/100,000),而最北端的州最低。
■符合全球趋势,澳大利亚的MS患病率正在上升,特别是在高纬度地区。MS预防对于阻止这种令人不安的趋势至关重要。
UNASSIGNED: Multiple sclerosis (MS) prevalence is increasing globally.
UNASSIGNED: To determine whether increased prevalence is continuing within Australia using our validated prescription-based ascertainment method.
UNASSIGNED: We used methods employed in our 2010 and 2017 prevalence estimates. Disease-modifying therapy (DMT) prescriptions were extracted from Australia\'s Pharmaceutical Benefits Scheme data for January-December 2021. DMT penetrance was calculated using data from the Australian MS Longitudinal Study. We divided the total number of monthly prescriptions by 12 or 2 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised. 2021 prevalence estimates were compared with 2010 and 2017 prevalence estimates using Poisson regression.
UNASSIGNED: Number of people with MS in Australia in 2021 was 33,335; an increase of 7728 from 2017 (30.2%) and 12,092 from 2010 (56.6%) and increasing at a faster rate than population change (+10.1%, +14.1%). Age-standardised prevalence was 136.1/100,000 (increased from 103.7/100,000 in 2017). The previously demonstrated positive latitudinal gradient in 2010 and 2017 persisted in 2021, with Tasmania (southernmost state) having the highest prevalence (age-standardised: 203.5/100,000) while northernmost states had the lowest.
UNASSIGNED: In line with global trends, MS prevalence is escalating in Australia, particularly in higher-
latitude states. MS prevention is crucial to halt this disturbing trend.